PEOPLE - Refocus (US) makes appointment:
This article was originally published in Clinica
Executive Summary
Refocus (Dallas, Texas), a medical device company focused on developing treatments for eye disorders, has appointed Glen Bradley and Melvyn Estry as chairmen of the board. They replace Ronald Schachar who founded the company which was formerly known as Presby Corp. Also appointed to the board are president and CEO Terrence Walts, David Williams, Peter Hobbins, Robin Terrell, Abbey Butker and Grady Schleier. Refocus was known until recently as Presby (see Clinica No 1050, p 15).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.